In a groundbreaking move, Deloitte Digital and Salesforce have announced a transformative partnership aimed at accelerating innovation in the biopharmaceutical industry. The collaboration addresses a critical need for modernization, as legacy platforms have proven insufficient in keeping pace with the dynamic advancements in therapy development and patient-centric care.
Deloitte's CIO, Brett Davis, emphasized the urgency of this modernization, highlighting the industry's remarkable progress in therapies and personalized medicine. Established platforms no longer align with the evolving requirements of research, development, and commercial interactions in the BioPharma sector. This partnership with Salesforce signifies a commitment to pioneering next-generation technologies that will propel scientific and technological advancements in the industry.
Amit Khanna, Salesforce SVP and GM of Health and Life Sciences, underlined the imperative nature of technology modernization in BioPharma. With healthcare innovation advancing at a rapid pace, the transformation of outdated systems and the creation of new engagement models are essential. This collaboration promises to revolutionize the entire value chain, from clinical to commercial, expediting the development and commercialization of groundbreaking medications.
The expertise brought forth by Deloitte Digital and Salesforce is poised to be a game-changer for biopharmaceutical companies. David Rosner, Head of Life Sciences at Deloitte Digital, highlighted their deep understanding of the industry, which will serve as a valuable asset in the partnership. Their combined intellectual capital and global industry knowledge will enable Salesforce's product team to tailor solutions that directly address industry concerns. This fusion of expertise in therapy development and healthcare delivery will result in technologically advanced and globally relevant solutions.
The BioPharma consumer engagement revolution is now underway. Deloitte Digital and Salesforce are committed to seamlessly integrating new technology with industry demands to benefit patients, healthcare providers, and the sector as a whole. By providing faster and more effective treatments and cures, this collaboration is set to propel BioPharma into a new era of success.
Deloitte Digital's presence at Dreamforce 2023 further underscores their dedication to advancing the industry. As a Pioneer Sponsor, they will offer a platform for hands-on learning. workshops and collaboration focused on AI, data, and CRM. This event signifies their commitment to pushing the boundaries of what is possible in the biopharmaceutical sector.
This collaboration is not only a promise but a catalyst for a future where patients receive faster, more effective treatments and where BioPharma companies can deliver groundbreaking therapies with unparalleled speed and precision.